Gary L. Buchschacher Jr., MD, PhD ...

Dr. Gary L. Buchschacher

Claim this profile

Kaiser Permanente-Anaheim

Studies Colon Cancer
Studies Colorectal Cancer
14 reported clinical trials
34 drugs studied

Area of expertise

1

Colon Cancer

Gary L. Buchschacher has run 5 trials for Colon Cancer. Some of their research focus areas include:

Stage IV
Stage III
BRAF negative
2

Colorectal Cancer

Gary L. Buchschacher has run 3 trials for Colorectal Cancer. Some of their research focus areas include:

Stage III
Stage IV
Stage I

Affiliated Hospitals

Image of trial facility.

Kaiser Permanente-Anaheim

Image of trial facility.

Kaiser Permanente-Bellflower

Clinical Trials Gary L. Buchschacher is currently running

Image of trial facility.

Nivolumab + Standard Treatment

for Stomach and Esophageal Cancer

This phase II/III trial compares the addition of nivolumab to the usual treatment of paclitaxel and ramucirumab to paclitaxel and ramucirumab alone in treating patients with gastric or esophageal adenocarcinoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Adding nivolumab to ramucirumab and paclitaxel may work better to treat patients with advanced stomach or esophageal cancer.

Recruiting

1 award

Phase 2 & 3

20 criteria

Image of trial facility.

Perioperative Chemotherapy

for Pancreatic Cancer

This phase III trial compares perioperative chemotherapy (given before and after surgery) versus adjuvant chemotherapy (given after surgery) for the treatment of pancreatic cancer that can be removed by surgery (removable/resectable). Chemotherapy drugs, such as fluorouracil, irinotecan, leucovorin, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before and after surgery (perioperatively) may work better in treating patients with pancreatic cancer compared to giving chemotherapy after surgery (adjuvantly).

Recruiting

4 awards

Phase 3

18 criteria

More about Gary L. Buchschacher

Clinical Trial Related

8 years of experience running clinical trials · Led 14 trials as a Principal Investigator · 4 Active Clinical Trials

Treatments Gary L. Buchschacher has experience with

  • Fluorouracil
  • Irinotecan Hydrochloride
  • Leucovorin
  • Leucovorin Calcium
  • Oxaliplatin
  • Paclitaxel

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Gary L. Buchschacher specialize in?

Is Gary L. Buchschacher currently recruiting for clinical trials?

Are there any treatments that Gary L. Buchschacher has studied deeply?

What is the best way to schedule an appointment with Gary L. Buchschacher?

What is the office address of Gary L. Buchschacher?

Is there any support for travel costs?